English NewsSunday, 15 November 2026
Latest
Medical

The new Alzheimer's blood test and what it means for diagnosis

2026-01-12

The new Alzheimer's blood test and what it means for diagnosis
Photo: CC BY 2.0

Diagnosing Alzheimer's disease became far simpler and cheaper in May 2025, when the FDA cleared the first blood test for early detection. It is meant for people aged 55 and over who show signs or symptoms of the disease.

The test, Lumipulse, is not the only assay hunting for Alzheimer's markers in blood - but it is the first to survive the demanding regulatory approval process, a milestone widely seen as a game changer.

To understand why it matters and what it could change, we spoke with a neurologist who specialises in memory disorders.

Q. Why is Lumipulse watched so closely when doctors can already order similar blood tests?

A: Several accurate Alzheimer's blood tests exist in clinical use, and some are marketed straight to consumers. But without FDA approval, FDA safety oversight, and public and private insurance coverage, none has entered the standard of care - they have simply been novel tests people pay for themselves, sometimes $300 to $1,750 depending on the company. Financial help is occasionally available.

Until now, confirming Alzheimer's has relied on two more complex, invasive, and expensive FDA-approved options that insurance does cover: a PET scan of the brain, or a lumbar puncture ("spinal tap") that detects disease biomarkers in the fluid around the brain and spinal cord.

Q. What does FDA approval of Lumipulse change?

A: Approval signals that scientists have evaluated the test, that it performs as claimed, and that it can genuinely benefit patient care.

The next step is insurance coverage, especially from Medicare and Medicaid. If that arrives soon, as expected, the test will likely become the standard of care - a fast route to detecting Alzheimer's that lets treatment begin immediately.

Q. How does Lumipulse work?

A: It analyses a blood sample for proteins characteristic of Alzheimer's disease. It computes the ratio of amyloid-beta 40 - naturally present and considered normal - to amyloid-beta 42, which helps form the brain plaques of Alzheimer's. It also measures phosphorylated tau 217, a form of tau protein tied to tangles inside brain cells.

Roughly 80% of the time the result is strongly positive or strongly negative, and those calls are accurate more than 90% of the time. The remaining 20% of results are inconclusive.

Q. How would doctors use Lumipulse if insurance covers it?

A: A clearly negative result brings reassuring news, with a plan to revisit memory concerns in six months. If problems persist, the patient sees a memory specialist to hunt for other causes of dementia. An inconclusive result sends the patient for an amyloid PET scan or a lumbar puncture to settle the diagnosis.

A positive result leads to a neurologist or another specialist to discuss treatment, such as an amyloid-targeting therapy.

Q. Will more Alzheimer's blood tests be approved?

A: Very likely several will win FDA clearance quickly. Now that disease-modifying treatments for Alzheimer's exist, finding and treating patients fast has become pressing.

More Medical news